188 related articles for article (PubMed ID: 16804637)
41. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.
Sadowski MJ; Pankiewicz J; Scholtzova H; Mehta PD; Prelli F; Quartermain D; Wisniewski T
Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18787-92. PubMed ID: 17116874
[TBL] [Abstract][Full Text] [Related]
42. Alzheimer's disease amyloid-β pathology in the lens of the eye.
Moncaster JA; Moir RD; Burton MA; Chadwick O; Minaeva O; Alvarez VE; Ericsson M; Clark JI; McKee AC; Tanzi RE; Goldstein LE
Exp Eye Res; 2022 Aug; 221():108974. PubMed ID: 35202705
[TBL] [Abstract][Full Text] [Related]
43. Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-β levels in brain.
Henderson BW; Gentry EG; Rush T; Troncoso JC; Thambisetty M; Montine TJ; Herskowitz JH
J Neurochem; 2016 Aug; 138(4):525-31. PubMed ID: 27246255
[TBL] [Abstract][Full Text] [Related]
44. Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment.
Montoliu-Gaya L; Villegas S
Expert Rev Mol Med; 2016 Jun; 18():e13. PubMed ID: 27357999
[TBL] [Abstract][Full Text] [Related]
45. γ-secretase binding sites in aged and Alzheimer's disease human cerebrum: the choroid plexus as a putative origin of CSF Aβ.
Liu F; Xue ZQ; Deng SH; Kun X; Luo XG; Patrylo PR; Rose GM; Cai H; Struble RG; Cai Y; Yan XX
Eur J Neurosci; 2013 May; 37(10):1714-25. PubMed ID: 23432732
[TBL] [Abstract][Full Text] [Related]
46. Alpha-Linolenic Acid from Perilla frutescens var. japonica Oil Protects Aβ-Induced Cognitive Impairment through Regulation of APP Processing and Aβ Degradation.
Lee AY; Lee MH; Lee S; Cho EJ
J Agric Food Chem; 2017 Dec; 65(49):10719-10729. PubMed ID: 29092397
[TBL] [Abstract][Full Text] [Related]
47. The Beneficial Role of Exercise on Treating Alzheimer's Disease by Inhibiting β-Amyloid Peptide.
Tan ZX; Dong F; Wu LY; Feng YS; Zhang F
Mol Neurobiol; 2021 Nov; 58(11):5890-5906. PubMed ID: 34415486
[TBL] [Abstract][Full Text] [Related]
48. Analysis of Non-Amyloidogenic Mutations in APP Supports Loss of Function Hypothesis of Alzheimer's Disease.
Kim M; Bezprozvanny I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768421
[TBL] [Abstract][Full Text] [Related]
49. Hydrophilic loop 1 of Presenilin-1 and the APP GxxxG transmembrane motif regulate γ-secretase function in generating Alzheimer-causing Aβ peptides.
Liu L; Lauro BM; Wolfe MS; Selkoe DJ
J Biol Chem; 2021; 296():100393. PubMed ID: 33571524
[TBL] [Abstract][Full Text] [Related]
50. Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension.
Mao P; Manczak M; Calkins MJ; Truong Q; Reddy TP; Reddy AP; Shirendeb U; Lo HH; Rabinovitch PS; Reddy PH
Hum Mol Genet; 2012 Jul; 21(13):2973-90. PubMed ID: 22492996
[TBL] [Abstract][Full Text] [Related]
51. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
Asai M; Kawakubo T; Mori R; Iwata N
Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
[TBL] [Abstract][Full Text] [Related]
52. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
Blennow K; Hampel H; Zetterberg H
Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
[TBL] [Abstract][Full Text] [Related]
53. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology.
Fukami S; Watanabe K; Iwata N; Haraoka J; Lu B; Gerard NP; Gerard C; Fraser P; Westaway D; St George-Hyslop P; Saido TC
Neurosci Res; 2002 May; 43(1):39-56. PubMed ID: 12074840
[TBL] [Abstract][Full Text] [Related]
54. The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease.
Ling S; Zhou J; Rudd JA; Hu Z; Fang M
Anat Rec (Hoboken); 2011 Aug; 294(8):1307-18. PubMed ID: 21717585
[TBL] [Abstract][Full Text] [Related]
55. Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer's Disease.
Sikanyika NL; Parkington HC; Smith AI; Kuruppu S
Neurochem Res; 2019 Jun; 44(6):1289-1296. PubMed ID: 30806879
[TBL] [Abstract][Full Text] [Related]
56. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
Hüttenrauch M; Baches S; Gerth J; Bayer TA; Weggen S; Wirths O
J Alzheimers Dis; 2015; 44(4):1291-302. PubMed ID: 25408216
[TBL] [Abstract][Full Text] [Related]
57. Pyroglutamate-Aβ: role in the natural history of Alzheimer's disease.
Gunn AP; Masters CL; Cherny RA
Int J Biochem Cell Biol; 2010 Dec; 42(12):1915-8. PubMed ID: 20833262
[TBL] [Abstract][Full Text] [Related]
58. Genes and mechanisms involved in beta-amyloid generation and Alzheimer's disease.
Steiner H; Capell A; Leimer U; Haass C
Eur Arch Psychiatry Clin Neurosci; 1999; 249(6):266-70. PubMed ID: 10653281
[TBL] [Abstract][Full Text] [Related]
59. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
Barage SH; Sonawane KD
Neuropeptides; 2015 Aug; 52():1-18. PubMed ID: 26149638
[TBL] [Abstract][Full Text] [Related]
60. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
